Our Gastrointestinal Cancer Risk Evaluation Program at Penn Medicine's Abramson Cancer Center has specialists nationally recognized for their expertise in cancer and genetics. We provide information, care and support to help you throughout the entire risk evaluation program.
Penn's GI Cancer Risk team is familiar with and able to provide clinical, genetic and research services for people with concerns about the following conditions:
- Hereditary and familial colon cancer: Diseases including familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome predisposes people to develop colon polyps, which are benign growths and colon cancer. An early diagnosis combined with appropriate treatment and follow-up can dramatically lower the chances of developing colon cancer. In addition, other conditions that are evaluated include: MYH associated polyposis (MAP), Peutz-Jeghers syndrome and Juvenile Polypsis.
- Hereditary and familial pancreatic cancer: This includes those with BRCA2, p16INK4a or SKT11 mutations as well as those with family history.
- Barrett's esophagus
- Esophageal cancer
- Stomach cancer: This includes those with the E-cadherin mutation.
- Gastrointestinal sarcomas